Metabolism and Pharmacokinetics

ds_metabolism_pk_section.jpg

The Metabolism and Pharmacokinetics (MAP) Group studies the pharmacokinetic profile (exposure over time) and metabolic fate of new drug compounds using a series of in silico, in vitro and in vivo studies. The group also assesses physical properties such as solubility and lipophilicity, and how these relate to the exposure profile and pharmacological effects.

MAP is an integral part of compound optimization and aspects of Absorption, Distribution, Metabolism, and Excretion (ADME).  ADME studies provide critical information for deciding which compounds to select for clinical studies or as starting points (leads) for compound optimization activities.

MAP engages in pharmacokinetic profiling such as ADME studies using in silico, in vitro, and in vivo techniques.

 

Selected publications

Wang J.; Urban L.; Bojanic D. Maximizing use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opinion Drug Metabolism Toxicology, (2007); 3(5): 641-665.

Wohnsland F.; Faller B.. High-Throughput Permeability pH Profile and High-Throughput Alkane/Water log P with Artificial Membranes. Journal of Medicinal Chemistry. (2001); 44(6): 923-930.